Especially, significant progresses were achieved in the treatment of non-small-cell lung cancers using EGFR-targeting therapeutics (Kelloff et al., 1996; Mukherji and Spicer, 2009; Ou, 2012; Liao et al., 2015; Minari et al., 2016; Chen et al., 2019; Wright and Goss, 2019; Rebuzzi et al., 2020). Here, EGFR is linked to non-small cell lung carcinoma.